Safinamide (133865-89-1) is a selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A.1?Displays anticonvulsant activity2?and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models3. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade.4?A novel therapeutic for Parkinson’s disease with multiple modes of action.5?Effective as an add-on to dopamine agonist therapy in early Parkinson’s.6
Safinamide is an α-aminoamide derivative with a multimodal mechanism of action involving both dopaminergic and non-dopaminergic properties. It increases levels of available dopamine through dopamine reuptake inhibition andMAO-B inhibition. It is a potent and reversible inhibitor of MAO-B, with significantly greater selectivity for MAO-B over MAO-A than selegiline and rasagiline. However, it also has an important and novel mode of action that involves blockade of Na+ channels andmodulation of Ca2+ channels that inhibits glutamate release and therefore may provide a level of cognitive improvement and neuroprotection. Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. In PD, this relationship is altered, resulting in upregulation of cortico-striatal glutamatergic function in l-dopa-induced dyskinesia. Any drug that can counteract such unbalance in glutamate function is potentially useful in controlling dyskinesias.
Safinamide was originated by Farmitalia Carlo Erba, a company that was later purchased by Pharmacia. Newron Pharmaceuticals was established as a spin-off of Pharmacia in 1999 and acquired safinamide rights and intellectual property from Pharmacia Corporation. Newron originally granted Serono exclusive worldwide rights to develop, manufacture, and commercialize safinamide in 2006. However, in October 2011, Merck Serono agreed to return full global rights for safinamide to Newron. Newron then finalized a strategic collaboration and license agreement with Zambon for the worldwide development and commercialization of safinamide.
In 2003 positive preliminary results from a phase II trial of safinamide in epilepsy were announced. This open-labeled study was initiated to assess tolerability and drug–drug interaction (DDI) of safinamide in 48 patients with uncontrolled seizures that had already been treated with up to three other antiepileptic drugs. Starting with an initial oral dose of 50mg d−1, safinamide was increased every two weeks up to 300 mg d−1 or to the maximum tolerated dose. An interim analysis of the first 29 patients who completed the study showed excellent tolerability. In this group, no DDI was noted at any of the tested doses in that safinamide did not alter the kinetics of the other antiepileptic drugs. In this interim analysis safinamide was shown to be well tolerated in patients with medically intractable seizures. No serious AEs occurred in the study. Even though the study was not designed and powered to provide proof of efficacy, the sponsor reported that preliminary data showed a significant reduction in median seizure frequency from 50mg progressing up to the highest dose.
In 2005 safinamide was administered to a total of 10 patients with RLS that were enrolled into a single-center, phase II open-labeled pilot study. Each patient was administered safinamide (100 mg d−1) at bedtime for 2 weeks. A significant improvement in all efficacy parameters studied was observed when patients received safinamide. RLS is a neurological disorder characterized by jerky movements of the lower extremities that appear mostly in the evening and during sleep. As reported in a press release, safinamide was also found to be well tolerated and did not exhibit any clinically relevant side effects, but no study results have been published.
ChEBI: Safinamide is an amino acid amide.
Safinamide may exert its in vivo effects through different mechanisms of action. It did not display activity against >80 different types of dopamine, glutamate, adenosine, serotonin, muscarinic, nicotinic, and GABA receptors. Conversely, potent modulation of DA metabolism, blockade of Na+/Ca2+ channels, and inhibition of glutamate release have been demonstrated. It has pointed out that the electrophysiological and neurochemical effects of safinamide are apparent at effective anticonvulsant concentrations. For example, pharmacokinetics (PK) showed that brain levels reach roughly 40 μM, at 30 and 60min after an oral dose of 10 mg kg?1 safinamide in rats. These points in time correspond to the peak anticonvulsant effect observed in the MES epilepsy model. This micromolar concentration approximates the concentration of safinamide that gives effective inhibition of excitatory amino acid release and reduction of sustained repetitive firing (SRF). Importantly, safinamide partitions itself well into the brain, where drug levels are approximately 10-fold higher than in plasma.
Highly selective and reversible MAO-B inhibitor:
Treatment of Parkinson’s disease
General procedure for the synthesis of (S)-2-(4-(3-fluorobenzyloxy)benzylamino)propionamide from safinamide impurity 16: 84.41 g (0.68 mol) of L-alanine amide hydrochloride was dissolved in 1300 ml of methanol and added to a reaction flask. Subsequently 171.42g (1.69mol) of triethylamine was added and stirred at room temperature for 30 minutes. Then 4-(3-fluorobenzyloxy)benzaldehyde 130.1 g (0.56 mol) was added and stirring was continued for 2 hours at room temperature. Potassium borohydride 182.71 g (3.39 mol) was added to the reaction system and stirred overnight. After completion of the reaction, the reaction solution was concentrated to dryness, 1300 ml of water was added and stirred at room temperature for 1 h. Filtering was carried out. The resulting solid was dried under vacuum at 40 °C for 4 h. A white solid (S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide 163.92 g was obtained in 96.0% yield and 99.04% purity by HPLC.
Potentially hazardous interactions with other drugs
Analgesics: avoid with pethidine.
Antibacterials: possible enhanced hypotensive effect
with linezolid and tedizolid.
Antidepressants: increased risk of hypertension
and CNS excitation with SSRIs and tricyclics -
adjust SSRI or tricyclic doses, avoid or adjust dose
of fluoxetine and fluvoxamine; possible enhanced
hypotensive effect with MAOIs and moclobemide -
avoid.
Sympathomimetics: use with caution.
There are three routes of hepatic metabolism. The main
route involves hydrolytic oxidation of the amide moiety
leading to the main metabolite safinamide acid (NW-
1153). Another pathway involves oxidative cleavage of
the ether bond forming 'O-debenzylated safinamide'
(NW-1199). Finally the 'N-dealkylated acid' (NW-1689)
is formed by oxidative cleavage of the amine bond of
either safinamide (minor) or the primary safinamide acid
metabolite (NW-1153) (major). The 'N-dealkylated acid'
(NW-1689) undergoes conjugation with glucuronic acid
yielding its acyl glucuronide. None of these metabolites
are pharmacologically active.
In humans, safinamide is almost exclusively eliminated via
metabolism of which 76% is renal and 1.5% via the faeces.
[1] M. STROLIN BENEDETTI. The Anticonvulsant FCE 26743 is a Selective and Short-acting MAO-B Inhibitor Devoid of Inducing Properties towards Cytochrome P450-dependent Testosterone Hydroxylation in Mice and Rats[J]. Journal of Pharmacy and Pharmacology, 1994, 46 10: 814-819. DOI:
10.1111/j.2042-7158.1994.tb03736.x[2] R G FARIELLO. Preclinical evaluation of PNU-151774E as a novel anticonvulsant.[J]. Journal of Pharmacology and Experimental Therapeutics, 1998, 285 2: 397-403.
[3] ROBERTO MAJ. PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat[J]. European journal of pharmacology, 1998, 359 1: Pages 27-32. DOI:
10.1016/s0014-2999(98)00554-8[4] F GARDONI. Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.[J]. Journal of Pharmacology and Experimental Therapeutics, 2018, 367 3: 442-451. DOI:
10.1124/jpet.118.251645[5] C CACCIA. Safinamide: from molecular targets to a new anti-Parkinson drug.[J]. Neurology, 2006, 67 7 Suppl 2: S18-23. DOI:
10.1212/wnl.67.7\_suppl\_2.s18[6] A. H. V. SCHAPIRA. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease[J]. European Journal of Neurology, 2012, 20 2: 271-280. DOI:
10.1111/j.1468-1331.2012.03840.x
